Economics and Cost of Care of Stone Disease

Advances in Chronic Kidney Disease

Volumn 16, Issue 1, 2009, Pages 5-10

  Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cost; Economics; Nephrolithiasis; Stones

Indexed keywords

ARTICLE; COST CONTROL; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DIETARY INTAKE; FLUID INTAKE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LENGTH OF STAY; MEDICAL FEE; NEPHROLITHIASIS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN; PRIORITY JOURNAL; RECURRENT DISEASE; REIMBURSEMENT; RENAL PROTECTION; SALT INTAKE; SECONDARY PREVENTION;

HEALTH CARE COSTS; HUMANS; NEPHROLITHIASIS; PREVALENCE; UNITED STATES;

EID: 57449108058     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.10.002     Document Type: Article

References (31)

1. Cowan C.A., Lazenby H.C., Martin A.B., et al. National health expenditures. Health Care Financ Rev 21 (1998) 165-210 1999
2. Chandhoke P.S. Economics of urolithiasis: cost-effectiveness of therapies. Curr Opin Urol 11 (2001) 391-393
3. Stamatelou K.K., Francis M.E., Jones C.A., Nyberg L.M., and Curhan G.C. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63 (2003) 1817-1823
4. Ljunghall S. Incidence of upper urinary tract stones. Miner Electrolyte Metab 13 (1987) 220-227
5. Saigal C.S., Joyce G., and Timilsina A.R. Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management?. Kidney Int 68 (2005) 1808-1814
6. Pearle M.S., Calhoun E.A., and Curhan G.C. Urologic diseases in America project: urolithiasis. J Urol 173 (2005) 848-857
7. Clark J.Y., Thompson I.M., and Optenberg S.A. Economic impact of urolithiasis in the United States. J Urol 154 (1995) 2020-2024
8. Secker-Walker R.H., Vacek P.M., Hooper G.J., et al. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst 91 (1999) 702-708
9. Lotan Y., Cadeddu J.A., Roehrborn C.G., et al. The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol 172 (2004) 1958-1962
10. O'Leary M.P., Baum N.H., Blizzard R., et al. 2001 American Urological Association Gallup Survey: Changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol 168 (2002) 649-652
11. Escarce J.J. Effects of lower surgical fees on the use of physician services under Medicare. JAMA 269 (1993) 2513-2518
12. Morris D.S., Taub D.A., Wei J.T., et al. Regionalization of percutaneous nephrolithotomy: Evidence for the increasing burden of care on tertiary centers. J Urol 176 (2006) 242-246
13. Landman J., Lee D.I., Lee C., et al. Evaluation of overall costs of currently available small flexible ureteroscopes. Urology 62 (2003) 218-222
14. Lotan Y., Gettman M.T., Roehrborn C.G., et al. Management of ureteral calculi: A cost comparison and decision making analysis. J Urol 167 (2002) 1621-1629
15. Hollingsworth J.M., Rogers M.A., Kaufman S.R., et al. Medical therapy to facilitate urinary stone passage: A meta-analysis. Lancet 368 (2006) 1171-1179
16. Bensalah K., Pearle M., and Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol 53 (2008) 411-419
17. Meschi T., Schianchi T., Ridolo E., et al. Body weight, diet and water intake in preventing stone disease. Urol Int 72 suppl 1 (2004) 29-33
18. Curhan G.C. Epidemiology of stone disease. Urol Clin North Am 34 (2007) 287-293
19. Curhan G.C., Willett W.C., Rimm E.B., et al. Body size and risk of kidney stones. J Am Soc Nephrol 9 (1998) 1645-1652
20. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
21. Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int 34 (1988) 544-555
22. Holmes R.P., Goodman H.O., and Assimos D.G. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 59 (2001) 270-276
23. Muldowney F.P., Freaney R., and Moloney M.F. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 22 (1982) 292-296
24. Lemann Jr. J., Gray R.W., Maierhofer W.J., and Cheung H.S. The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion. Kidney Int 29 (1986) 743-746
25. Borghi L., Schianchi T., Meschi T., et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346 (2002) 77-84
26. Borghi L., Meschi T., Amato F., et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 155 (1996) 839-843
27. Pearle M.S., Roehrborn C.G., and Pak C.Y. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13 (1999) 679-685
28. Parks J.H., and Coe F.L. The financial effects of kidney stone prevention. Kidney Int 50 (1996) 1706-1712
29. Lotan Y., Cadeddu J.A., Roerhborn C.G., et al. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol 172 (2004) 2275-2281
30. Hofbauer J., Hobarth K., Szabo N., et al. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis-A prospective randomized study. Br J Urol 73 (1994) 362-365
31. Ettinger B., Citron J.T., Livermore B., et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139 (1988) 679-684